SAN FRANCISCO - Vir Biotechnology, Inc. (NASDAQ: NASDAQ:VIR), a company specializing in immunology and infectious diseases, announced the upcoming departure of its Chief Medical Officer, Phil Pang, M.D., Ph.D., who will be leaving the company at the end of March 2024 to focus on family time. The firm is actively searching for his successor.
Dr. Pang has been recognized for his leadership role in the development of sotrovimab, a therapeutic agent used during the height of the COVID-19 pandemic. His expertise in infectious diseases contributed to the company's efforts to address global health challenges such as chronic hepatitis delta, hepatitis B, and HIV. "He leaves behind a strong team of drug developers, positioning us well for continued success," remarked Marianne De Backer, Vir's CEO.
Reflecting on his tenure, Dr. Pang expressed pride in the company's achievements and confidence in the team's ability to maintain momentum in the transition period. "I am inspired by Marianne's vision of the future at Vir, and I look forward to continuing to watch the company flourish," he said.
Vir Biotechnology focuses on leveraging the immune system to treat and prevent serious infectious diseases. The company has established two technology platforms aimed at enhancing immune responses, and its clinical pipeline includes candidates targeting hepatitis delta and B viruses, as well as HIV. Vir also has several preclinical candidates, including those for influenza, COVID-19, RSV/MPV, and HPV.
It should be noted that early-stage clinical trial results may not be indicative of full results from later-stage trials and do not guarantee regulatory approval. Vir has not disclosed any further details regarding the transition or potential candidates for the CMO position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.